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Better insight into hematopoietic stem cell (HSC) development in the human embryo and fetus is crucial for
translational research. In this issue ofCell StemCell, Prashad et al. (2014) describe a novel surface marker for
human fetal liver HSCs, glycosylphosphatidylinositol-anchored protein GPI-80, that is functionally required
for their self-renewal.Over the last 2 decades, the use of HSC
transplantation in the clinic has increased
due to improved preconditioning regi-
mens, resulting in an expanding list of
therapeutic indications (Gratwohl et al.,
2010). The shortage of suitable donors
is a major obstacle for clinical HSC
transplantation. Many research groups
are developing strategies for generating
human HSCs from ESCs/iPSCs under
laboratory conditions, which would pro-
vide an unlimited supply of transplant-
able HSCs for clinical use. Although
promising, this approach remains a chal-
lenging task. A better understanding of
HSC development during human embry-
onic and fetal stages may help us to
design innovative protocols for produc-
tion of these cells in vitro.
Another issue that limits translational
research in this area is our inability to
isolate human HSCs with high purity to
study molecular mechanisms underlying
their self-renewal. Although it has been
possible to enrich HSC activity to 1 in
10–20 human umbilical cord blood cells
(Majeti et al., 2007; Notta et al., 2011),
the search for uniquely specific human
HSC surfacemarkers continues (Doulatov
et al., 2012).
To gain an insight into possible mecha-
nistic blocks in the differentiation of
human ESCs/iPSCs into HSCs, Mikkola
and colleagues have focused in this issue
ofCell Stem Cell on the analysis of human
fetal liver HSCs, which are developmen-
tally closer to ESCs/iPSCs than umbili-
cal cord blood or bone-marrow-derived
HSCs (Prashad et al., 2014). They
confirmed the usefulness of markers pre-
viously identified for human umbilical cord
blood HSCs (Majeti et al., 2007) and
showed that the CD34+CD38/loCD90+,
but not the CD34+CD38/loCD90, cell
population harbors practically all HSCsin the second trimester human fetal
liver. Differential gene expression anal-
ysis showed considerably higher ex-
pression levels of glycosylphosphatidyli-
nositol-anchored protein GPI-80 in the
CD34+CD38/loCD90+ cell fraction. The
authors hypothesized that GPI-80
marks human fetal liver HSCs and is
important for their function. In vitro
checks demonstrated that, although
both the CD34+CD38/loCD90+GPI-80+
and CD34+CD38/loCD90+GPI-80- cell
populations possess multilineage differ-
entiation potential, only the former could
robustly expand in culture. In vivo long-
term repopulation studies using immuno-
deficient NOD.Cg-Prkdcscid Il2rgtm1Wjl/Sz
(NSG) mice confirmed that all HSCs
in the human fetal liver are GPI-80+.
Introduction of the additional GPI-80
marker gave a significant four-fold
enrichment of HSC activity within the
CD34+CD38/loCD90+ cell population.
Although this strategy enabled elimination
of GPI-80 hematopoietic progenitors,
further identification of novel markers will
be required to remove remaining GPI-
80+ hematopoietic progenitors to obtain
an entirely pure HSC population.
The team knew that GPI-80 is involved
in regulation of integrin-mediated neutro-
phil trafficking (Huang et al., 2004)
and therefore investigated its possible
function in human fetal liver HSCs.
To this end, they first analyzed the
molecular signature of the enriched
CD34+CD38/loCD90+GPI-80+ cell popu-
lation using a transcriptomics approach.
The authors found strong similarities be-
tween the CD34+CD38/loCD90+GPI-80+
and CD34+CD38/loCD90+GPI-80 cell
populations in terms of expression of
transcription factors involved in HSC
specification and maintenance. However,
among approximately 800 differentiallyCell Stem Celexpressed genes, close to the top of
the list was ITGAM (integrin a-M), a
component of the MAC-1 complex known
to colocalize with GPI-80 on neutrophils.
The authors tested the functional signifi-
cance of both GPI-80 and ITGAM by
lentiviral shRNA knockdown. Knockdown
of either gene compromised the ability
of CD34+CD38/loCD90+GPI-80+ cells to
expand in vitro and repopulate immuno-
deficient recipient mice, suggesting their
involvement in self-renewal. Prashad
et al. (2014) propose that GPI-80 and
ITGAM cooperate to transmit the niche
signals protecting the ‘‘stemness’’ of
HSCs. Future studies will show whether
mechanisms employed by neutrophils
for cell adhesion andmigration are utilized
by HSCs to maintain their self-renewal.
It is known that both mouse and human
HSC pools are highly heterogeneous
in terms of their quiescence status, self-
renewal capacity, and differentiation
ability (Copley et al., 2012). For example,
human fetal liver HSCs are split into
more powerful (highly self-renewable)
VE-cadherin+ and less powerful VE-
cadherin subsets (Oberlin et al., 2010).
In future studies, it will be interesting to
investigate whether differences in levels
of GPI-80 expression can reveal HSC
heterogeneity.
Human HSCs emerge first in the
aorta-gonad-mesonephros (AGM) region,
specifically in the ventral domain of the
dorsal aorta, and only later appear in the
yolk sac, liver, and placenta (Ivanovs
et al., 2014; Ivanovs et al., 2011). The
establishment of the markers identifying
the first human HSCs during develop-
ment would be highly important for
understandingmechanisms of HSC spec-
ification and expansion during embryo-
genesis. Mikkola and colleagues identi-
fied CD34+CD38/loCD90+GPI-80+ cellsl 16, January 8, 2015 ª2015 Elsevier Inc. 5
Figure 1. Sequence of Appearance of HSCs during Human Development
Prashad et al. (2014) identified GPI-80+ HSCs in the second trimester human fetal liver. The GPI-80marker
could be tracked back to cells in the first trimester human placenta, although the placenta at this stage
does not contain HSCs (Ivanovs et al., 2011). It remains to be established whether GPI-80 marks the first
HSCs in the human AGM region and can be used to follow their migration between different hematopoietic
niches. CS, Carnegie stage.
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Previewsin the first trimester human placenta and
found that, similar to second trimester
human fetal liver cells, this placental cell
population possesses robust in vitro
expansion ability. Further in vivo long-
term repopulation studies will be required
to test whether GPI-80 could be used to
track the emergence of HSCs in the
AGM region and their migration during
development (Figure 1).
The paper by Prashad et al. (2014)
contributes to a better understanding of
mechanisms regulating human HSCs.6 Cell Stem Cell 16, January 8, 2015 ª2015 EGPI-80 is a novel surface marker for puri-
fication of human fetal liver HSCs andmay
become a more generic tool for purifica-
tion of HSCs from other sources. The
addition of this marker to the combination
of previously established HSC surface
markers narrows down the search for
the precise identity of human HSCs. It
is remarkable that GPI-80 is not only
a phenotypic marker but also an impor-
tant molecule for HSC biology. Dissection
of GPI-80 function could shed light
on mechanisms of interaction betweenlsevier Inc.human HSCs and their niches, which will
also be relevant to the analysis of HSC
homing and trafficking. Because GPI-80
can regulate cell proliferation, a question
for future research would be whether pro-
liferation/quiescence and interaction with
the HSC niche are linked at least partially
through action of this gene.REFERENCES
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